

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT HUISHENG BIOPHARMACEUTICAL'S SGLT-2 INHIBITOR INNOVATIVE DRUG PROLINE JANAGLIFLOZIN TABLETS OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, Proline Janagliflozin tablets (Trade Name: Huiyoujing (惠優靜®), “**Janagliflozin**”), a sodium glucose transporter 2 inhibitor (“**SGLT-2 inhibitor**”) and national Class 1 innovative drug, developed by Huisheng Biopharmaceutical Co., Ltd. (“**Huisheng Biopharmaceutical**”), a non-wholly owned subsidiary of the Group, has obtained drug registration approval from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**”) for the treatment of type 2 diabetes. This will be the second self-developed SGLT-2 inhibitor innovative drug approved and marketed in China, which marks the breakthrough progress of Huisheng Biopharmaceutical in the research and development of innovative drugs in the field of diabetes treatment.

The SGLT-2 inhibitor is a new type of oral hypoglycemic drug highly recommended internationally for the treatment of patients with type 2 diabetes mellitus. It selectively inhibits the SGLT-2 receptor in renal proximal tubules, to reduce glucose re-absorption and promote urinary glucose excretion, thus lowering blood glucose concentration. SGLT-2 inhibitors not only have good hypoglycemic effect, but also have multiple benefits such as cardiovascular and renal protection, which is recommended by domestic and foreign guidelines in multiple fields, and also have the potential to expand to cardiovascular disease, chronic kidney disease and other indications. Janagliflozin, as a SGLT-2 inhibitor, is a national Class 1 innovative drug, and its phase III clinical data showed that it not only has significant hypoglycemic

efficacy (the decrease of HbA1c is up to 1.4% compared to baseline), but also has multiple benefits such as lowering blood pressure, reducing weight and improving blood lipids, etc., with low risk of hypoglycemia, and good overall safety. When compared side-by-side with phase III clinical data of similar SGLT-2 inhibitor products already on the market, Janagliflozin showed similar or even better results. Huisheng Biopharmaceutical owns the patent rights of Janagliflozin in multiple countries and regions including China, the United States, Europe, Japan, South Korea and Hong Kong, etc.

According to the latest report of the International Diabetes Federation (IDF), there were 537 million adult diabetes patients in the world in 2021, with 140 million diabetes patients in China topping the list. SGLT-2 inhibitors, as hypoglycemic drugs with novel mechanism of action, have seen rapid growth in market size. According to CHPA data, the sales revenue of SGLT-2 inhibitor drugs in sample hospitals in China in 2022 was about RMB3.6 billion, with an increase of 46% compared to 2021.

ABOUT HUISHENG BIOPHARMACEUTICAL

Huisheng Biopharmaceutical is a biopharmaceutical company under Sihuan Pharmaceutical, a large domestic pharmaceutical and medical aesthetics group, focusing on the areas of diabetes and complications. After nine years of construction and development, Huisheng Biopharmaceutical has become one of the few companies in China that has achieved full product coverage in the field of diabetes and related complications, and integrated the whole industrial chain of R&D, production and sales. The company currently has a world-class R&D team with rich experience in diabetes drug research and development. At present, it has more than 40 products in the research product pipeline of diabetes and complications, covering a full range of second-, third-, and new-generation insulin (covering basic, premixed and quick-acting etc.), innovative drugs with the latest mechanism, such as SGLT-2 inhibitors, GLP-1 agonists, and other hypoglycemic drugs and complication drugs. Huisheng Biopharmaceutical is committed to providing full-process, all-round integrated treatment solutions for diabetic patients, serving patients and making health easier.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 23 January 2024

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.